The RSV vaccine is recommended for adults 75 and older, for adults 60 to 74 with risk conditions, and for pregnant people at 32 to 36 weeks gestation during RSV season. A monoclonal antibody is recommended for infants under 8 months born during or entering their first RSV season. The answer depends on age, health status, pregnancy timing, and which product is available. This guide explains the biology behind each threshold so you can map the recommendations onto your own situation.
What RSV does to an older adult
Respiratory syncytial virus is not a cold virus with a scary name. It is a paramyxovirus that fuses infected cells into clumps called syncytia, which lets it spread cell-to-cell without ever entering the bloodstream. That fusion strategy is why the virus stays in the airway and why it hits small airways and older lungs so hard.
In an older adult, decades of exposure have left behind immune memory that is real but tired. Antibody levels drift downward, and the pool of naive T cells shrinks. The result is not an inability to fight the virus but a slower, less coordinated fight. Viral shedding lasts longer, inflammation lingers, and the lower airway takes collateral damage.
The vaccine approach is built around a structural fix. Early candidate vaccines used a prefusion-unstable form of the fusion protein, and the immune system responded to shapes that do not exist on the real virus. Modern vaccines lock the protein in its prefusion conformation, so the antibodies produced actually recognize the virus as it appears on entry. That is one reason this generation of vaccines works where older attempts did not.
Plain language: RSV physically merges cells together, and the newest vaccines train the immune system on the exact shape the virus uses to start that merger.
The numbers that drive the thresholds
Hospitalization risk from RSV climbs steeply with age and with the number of chronic conditions. Adults 65 and older account for a large share of RSV hospitalizations, and the rate in adults 75 and older is roughly double that of adults 65 to 74. In the oldest groups, RSV hospitalization burden approaches that of influenza in some seasons.
The risk is not only respiratory. RSV triggers systemic inflammation that can destabilize heart failure, provoke COPD exacerbations, and unmask arrhythmias. A portion of older adults hospitalized with RSV require intensive care, and a meaningful fraction die within a year of admission, though cause attribution in that window is difficult.
Timing matters because RSV seasonality in the United States runs roughly from October through March, with a peak in December and January in most years. Protection from vaccination is highest in the months immediately after administration. That creates a simple planning rule: get vaccinated before the season starts rather than in the middle of it.
Infants carry the heaviest burden of all. RSV is the leading cause of infant hospitalization in the first year of life in the US. Most severe cases occur in infants under 6 months, which is the group that cannot yet be vaccinated directly.
Where the recommendations get complicated
Three groups sit on the edge of the recommendations and deserve explicit treatment.
Adults 60 to 74 without risk conditions are in a shared clinical decision-making zone, not an automatic recommendation. The reasoning is that absolute benefit in this group is small enough that individual preference and local season intensity should tip the balance. If you are in this band and healthy, the question is not whether the vaccine works but whether your personal risk justifies it.
Pregnant people are recommended to receive a single dose at 32 to 36 weeks during RSV season, and the point is transplacental antibody transfer. Antibodies cross the placenta most efficiently in the third trimester, so timing the dose close to delivery maximizes the infant's antibody titer at birth. Vaccinating earlier in pregnancy is not harmful but wastes antibody decay before delivery.
Infants get a different tool entirely. Nirsevimab is a long-acting monoclonal antibody given as a single injection, not a vaccine. It provides passive immunity immediately, which matters because active vaccination cannot generate a protective response fast enough in a newborn. The choice between maternal vaccination and infant antibody depends on availability and timing, not on one being superior.
A counterintuitive caveat worth knowing: more vaccination is not automatically better for the same person. Neither the RSV vaccine nor nirsevimab is recommended as an annual repeat in every scenario, and re-dosing schedules differ between products. Do not treat RSV vaccination like a flu shot you get every fall without checking current guidance.
Comparison table: RSV prevention options by group
| Group | Product | Type | Typical timing | Key consideration |
|---|---|---|---|---|
| Adults 75 and older | RSV vaccine | Active | Before RSV season | Age alone qualifies |
| Adults 60 to 74 with risk conditions | RSV vaccine | Active | Before RSV season | Risk condition required |
| Adults 60 to 74, healthy | RSV vaccine | Active | Before RSV season | Shared decision only |
| Pregnant people | RSV vaccine | Active | 32 to 36 weeks, in season | Transplacental transfer |
| Infants under 8 months | Nirsevimab | Passive antibody | Birth or season entry | Immediate but temporary |
| High-risk young children | Nirsevimab | Passive antibody | Per guidance | Second season may apply |
The table shows a structural point: the vaccine and the antibody do different jobs. One trains an immune system, the other supplies ready-made antibodies. Matching the tool to the person matters more than picking the newer product.
Red flags that change the calculus
Severe COPD or asthma with prior hospitalization for a respiratory infection. Heart failure, especially with reduced ejection fraction or recent decompensation. Advanced kidney disease or dialysis dependence. Diabetes with complications, particularly vascular or renal involvement. Residence in a long-term care facility or other congregate setting. Immunocompromise from disease or treatment, though response to active vaccination may be reduced.
These conditions raise the probability that an RSV infection becomes a hospitalization rather than a bad week at home. If two or more apply, the arithmetic of benefit shifts toward vaccination even in the 60 to 74 band.
Practical steps and thresholds
Step one: identify your category. Age 75 or older is the simplest threshold, and it requires no risk assessment. Age 60 to 74 requires knowing whether at least one qualifying condition applies. Pregnancy requires knowing your gestational age and whether you are inside the RSV season window.
Step two: check timing against season. In most of the US, the practical window for older adult vaccination closes around the start of RSV circulation. Getting the dose in late summer or early fall front-loads protection for the months that matter.
Step three: reconcile conflicting signals explicitly. A 62-year-old with well-controlled hypertension only may hear one clinician say yes and another say wait. The correct frame is shared decision-making: the recommendation permits vaccination but does not mandate it, and the decision should reflect personal risk tolerance and local epidemiology.
Step four: for pregnancy, count backward from your due date. A dose at 32 to 36 weeks lands antibodies in the infant's bloodstream at delivery. A dose at 28 weeks is earlier than needed and leaves less antibody at birth.
Step five: for infants, ask specifically about nirsevimab availability. Supply and eligibility criteria for the antibody have varied by season, so the answer at your hospital may not match what you read online.
Limits, uncertainty, and what the guidance cannot settle
Vaccine effectiveness in older adults is real but not complete. Estimates from the first seasons show meaningful protection against RSV-associated lower respiratory tract disease, with point estimates varying by product and season. Protection against severe outcomes appears stronger than protection against any symptomatic infection. These are effectiveness figures measured during real circulation, not efficacy from controlled trials, and they will move as seasons accumulate.
The duration of protection is the largest open question. Antibody titers decline after vaccination, and the optimal booster interval is not established for every product and group. Anyone who tells you a precise re-dosing schedule with confidence is ahead of the evidence.
Cost and access vary by insurance arrangement and product. Prices for the vaccines and the antibody are not uniform, and coverage rules differ between Medicare, commercial plans, and Medicaid. Check your specific coverage rather than budgeting from a single quoted figure.
Finally, the recommendations themselves are under active revision as new trial data and post-licensure surveillance arrive. The categories described here reflect current authoritative guidance, but thresholds have shifted before and may shift again. Before acting, confirm the current recommendation with a qualified clinician who knows your history.
This article is general educational information, not a diagnosis, treatment plan, or individualized medical recommendation. It does not promise any outcome from vaccination or from declining it. For decisions about your own RSV prevention, consult a qualified local clinician who can review your age, conditions, pregnancy status, and coverage.